Doris Taylor Rejoins Miromatrix As Scientific Advisor

Miromatrix is excited to announce the appointment of Doris A. Taylor, Ph.D., FACC, FAHA as a key scientific advisor. Dr. Taylor's groundbreaking research on perfusion decellularization and recellularization, which was published in Nature Medicine in 2008, is the basis of Miromatrix' patented technology.

"I am extremely pleased to rejoin Miromatrix in a consulting role,” says Dr. Taylor. “I founded Miromatrix in 2008 to apply the technology I helped pioneer. Since leaving the company, I followed its progress and watched it develop a new industry standard for hernia and advanced wound care. I believe the company’s new leadership combined with my intimate knowledge of this leading-edge technology will help Miromatrix realize its goal of bringing whole organs to patients worldwide. It's an exciting time for the company and for me.”

“We are extremely delighted to have Dr. Taylor rejoin Miromatrix and be a part of our talented team as we continue on our mission to end the organ transplant waiting list,” says Jeff Ross, Ph.D., CEO of Miromatrix. “Dr. Taylor brings a wealth of scientific and regulatory knowledge that will continue to help us accelerate our goals to create lifesaving organs,” Dr. Ross adds.

Dr. Taylor is the Director, Regenerative Medicine Research and Director of the Center for Cell and Organ Biotechnology at the Texas Heart Institute in Houston. She holds faculty appointments at both Texas A&M and Rice University and is a Fellow of the American College of Cardiology; American Heart Association Basic

Science Council and Council on Functional Genomics and Translational Biology, among others.  She has published extensively, authoring or co-authoring more than 130 scientific publications. She has been recognized for breakthrough research related to cell therapy, stem cell biology, and tissue engineering based therapies.  In addition to her research director responsibilities at THI, she co-directs the Cardiovascular Cell Therapy Research Network (CCTRN) Biorepository and leads a cell and cytokine profiling core lab that serves multiple NIH, National Heart Lung and Blood Institute (NHLBI) networks, medical centers, and research foundations in the U.S. and Canada.

About Miromatrix
Miromatrix Medical Inc., is a Minnesota-based biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products such as MIROMESH® and MIRODERM® for soft tissue reinforcement and advanced wound care, respectively.  Miromatrix’ perfusion decellularization/recellularization technology is protected by a series of issued patents and pending patent applications in all major markets around the world. In addition to MIROMESH and MIRODERM, internal development programs at Miromatrix focus primarily on creating fully implantable human organs including livers, kidneys and heart products, with collaborators including The Mayo Clinic, Texas Heart Institute and Mount Sinai Hospital, and aim at eliminating the organ transplant waiting list.  For more information visit

Jeff Ross, Ph.D.
(952) 942-6000

August 7, 2017